{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:04:02Z","timestamp":1764133442614,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Atherosclerotic cardiovascular diseases are the leading cause of adverse outcomes in patients with type 2 diabetes, and all new anti-diabetic agents are mandated to undergo cardiovascular outcome trials (CVOTs). Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are incretin mimetics that reduce blood glucose levels with a low associated risk of hypoglycaemia. CVOTs with different GLP-1 RAs yielded different results in terms of major cardiovascular composite outcome (MACE), with some trials showing superiority in the treatment arm, whereas other simply displayed non-inferiority. More importantly, the significance of each component of MACE varied between drugs. This begs the question of whether these differences are due to dissimilarities between drugs or other factors, namely trial design, are at the root of these differences. We analyse the trial designs for all CVOTs with GLP-1 RAs and highlight important differences between them, namely in terms of definition of established cardiovascular disease, and discuss how these differences might explain the disparate results of the trials and preclude direct comparisons between them. We conclude that a fair comparison between GLP-1 RA CVOTs would involve post-hoc analysis re-grouping the patients into different cardiovascular risk categories based upon their baseline clinical parameters, in order to even out the criteria used to classify patients.<\/jats:p>","DOI":"10.1186\/s13098-021-00698-5","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T12:02:41Z","timestamp":1627387361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?"],"prefix":"10.1186","volume":"13","author":[{"given":"Miguel","family":"Melo","sequence":"first","affiliation":[]},{"given":"Cristina","family":"Gavina","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Silva-Nunes","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Andrade","sequence":"additional","affiliation":[]},{"given":"Davide","family":"Carvalho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"698_CR1","unstructured":"IDF - International Diabetes Federation. IDF Diabetes Atlas, 9th edn.. Brussels, Belgium; 2019. https:\/\/www.diabetesatlas.org. Accessed 8 Apr 2020"},{"issue":"2","key":"698_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","volume":"3","author":"AD Shah","year":"2015","unstructured":"Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people. Lancet Diabetes Endocrinol. 2015;3(2):105\u201313.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"698_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2015.7008","volume":"314","author":"E Di Angelantonio","year":"2015","unstructured":"Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52.","journal-title":"JAMA"},{"issue":"16","key":"698_CR4","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","volume":"370","author":"EW Gregg","year":"2014","unstructured":"Gregg EW, Li Y, Wang J, Rios Burrows N, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990\u20132010. N Engl J Med. 2014;370(16):1514\u201323.","journal-title":"N Engl J Med"},{"issue":"15","key":"698_CR5","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Eliasson B, Svensson A-M, Miftaraj M, et al. Mortality and cardiovascular disease in Type 1 and Type 2 diabetes. N Engl J Med. 2017;376(15):1407\u201318.","journal-title":"N Engl J Med"},{"issue":"1","key":"698_CR6","doi-asserted-by":"publisher","first-page":"e000765","DOI":"10.1136\/bmjdrc-2019-000765","volume":"7","author":"M Muilwijk","year":"2019","unstructured":"Muilwijk M, Ho F, Waddell H, Sillars A, Welsh P, Iliodromiti S, et al. Contribution of type 2 diabetes to all-cause mortality, cardiovascular disease incidence and cancer incidence in white Europeans and South Asians: Findings from the UK Biobank population-based cohort study. BMJ Open Diabetes Res Care. 2019;7(1):e000765.","journal-title":"BMJ Open Diabetes Res Care."},{"issue":"S1","key":"698_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/dom.13701","volume":"21","author":"M Bengaluru Jayanna","year":"2019","unstructured":"Bengaluru Jayanna M, Robinson JG. The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of \u201creal world\u201d practice in people with diabetes. Diabetes, Obes Metab. 2019;21(S1):17\u201327.","journal-title":"Diabetes, Obes Metab"},{"issue":"14","key":"698_CR8","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","volume":"381","author":"PG Steg","year":"2019","unstructured":"Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381(14):1309\u201320.","journal-title":"N Engl J Med"},{"key":"698_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.046448","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, et al. The role of combination antiplatelet and anticoagulation therapy in diabetes and cardiovascular disease: insights from the COMPASS Trial. Circulation. 2020. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046448.","journal-title":"Circulation"},{"issue":"(11_Suppl)","key":"698_CR10","first-page":"I-220-I-225","volume":"116","author":"S Mohammadi","year":"2007","unstructured":"Mohammadi S, Dagenais F, Mathieu P, Kingma JG, Doyle D, Lopez S, et al. Long-term impact of diabetes and its comorbidities in patients undergoing isolated primary coronary artery bypass graft surgery. Circulation. 2007;116((11_Suppl)):I-220-I\u2013225.","journal-title":"Circulation"},{"issue":"6","key":"698_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jacc.2007.04.051","volume":"50","author":"J Machecourt","year":"2007","unstructured":"Machecourt J, Danchin N, Lablanche JM, Fauvel JM, Bonnet JL, Marliere S, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients. J Am Coll Cardiol. 2007;50(6):501\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"698_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3949\/ccjm.80a.13030","volume":"80","author":"B Aggarwall","year":"2013","unstructured":"Aggarwall B, Goel S, Sabik J, Shishehbor M. The FREEDOM trial: In appropriate patients with diabetes and multivessel coronary artery disease, CABG beats PCI. Cleve Clin J Med. 2013;80(8):515\u201323.","journal-title":"Cleve Clin J Med"},{"issue":"6","key":"698_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacc.2018.11.001","volume":"73","author":"ME Farkouh","year":"2019","unstructured":"Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, et al. Long-term survival following multivessel revascularization in patients with diabetes. J Am Coll Cardiol. 2019;73(6):629\u201338.","journal-title":"J Am Coll Cardiol"},{"issue":"7258","key":"698_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405\u201312.","journal-title":"BMJ"},{"issue":"24","key":"698_CR15","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"Group TA to CCR in DS","year":"2008","unstructured":"Group TA to CCR in DS. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545\u201359.","journal-title":"N Engl J Med"},{"issue":"24","key":"698_CR16","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"Group TAC","year":"2008","unstructured":"Group TAC. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u201372.","journal-title":"N Engl J Med"},{"issue":"2","key":"698_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00125-017-4473-2","volume":"61","author":"L Agrawal","year":"2018","unstructured":"Agrawal L, Azad N, Bahn GD, Ge L, Reaven PD, Hayward RA, et al. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2018;61(2):295\u20139.","journal-title":"Diabetologia"},{"issue":"15","key":"698_CR18","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"24","key":"698_CR19","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med. 2007;356(24):2457\u201371.","journal-title":"N Engl J Med"},{"issue":"3","key":"698_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/dom.12591","volume":"18","author":"M Nauck","year":"2016","unstructured":"Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, Obes Metab. 2016;18(3):203\u201316.","journal-title":"Diabetes, Obes Metab"},{"issue":"5","key":"698_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ahj.2015.02.002","volume":"169","author":"R Bentley-Lewis","year":"2015","unstructured":"Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015;169(5):631-638.e7.","journal-title":"Am Heart J"},{"issue":"23","key":"698_CR22","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"5","key":"698_CR23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ahj.2013.07.012","volume":"166","author":"SP Marso","year":"2013","unstructured":"Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, et al. Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166(5):823-830.e5.","journal-title":"Am Heart J"},{"issue":"4","key":"698_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"698_CR25","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"key":"698_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ahj.2015.12.009","volume":"174","author":"RR Holman","year":"2016","unstructured":"Holman RR, Bethel MA, George J, Sourij H, Doran Z, Keenan J, et al. Rationale and design of the EXenatide Study of cardiovascular event lowering (EXSCEL) trial. Am Heart J. 2016;174:103\u201310.","journal-title":"Am Heart J"},{"key":"698_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2017.02.005","volume":"187","author":"RJ Mentz","year":"2017","unstructured":"Mentz RJ, Bethel MA, Gustavson S, Thompson VP, Pagidipati NJ, Buse JB, et al. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Am Heart J. 2017;187:1\u20139.","journal-title":"Am Heart J"},{"issue":"13","key":"698_CR28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"key":"698_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ahj.2018.03.030","volume":"203","author":"JB Green","year":"2018","unstructured":"Green JB, Hernandez AF, D\u2019Agostino RB, Granger CB, Janmohamed S, Jones NP, et al. Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus\u2014Rationale, design, and baseline characteristics. Am Heart J. 2018;203:30\u20138.","journal-title":"Am Heart J"},{"issue":"10157","key":"698_CR30","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"3","key":"698_CR31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/dom.13553","volume":"21","author":"SC Bain","year":"2019","unstructured":"Bain SC, Mosenzon O, Arechavaleta R, Bogda\u0144ski P, Comlekci A, Consoli A, et al. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab. 2019;21(3):499\u2013508.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"698_CR32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"698_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.13028","volume":"20","author":"HC Gerstein","year":"2018","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes ( REWIND ) trial on the cardiovascular effects of dulaglutide. Diabetes, Obes Metab. 2018;20(1):42\u20139.","journal-title":"Diabetes, Obes Metab"},{"issue":"10193","key":"698_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"9","key":"698_CR35","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.2337\/dc12-2410","volume":"36","author":"RR Henry","year":"2013","unstructured":"Henry RR, Rosenstock J, Logan DK, Alessi TR, Luskey K, Baron MA. Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes. Diab Care. 2013;36(9):2559\u201365.","journal-title":"Diab Care"},{"key":"698_CR36","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Buse JB, Azeem R, Prabhakar P, Kjems L, Huang H, et al. Efficacy and safety of ITCA 650, a novel drug-Device GLP-1 receptor agonist, in type 2 diabetes uncontrolled with oral antidiabetes drugs: The FREEDOM-1 trial. Diabetes Care. 41(2):333\u2013340.","DOI":"10.2337\/dc17-1306"},{"issue":"3","key":"698_CR37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2337\/dc17-1519","volume":"41","author":"RR Henry","year":"2018","unstructured":"Henry RR, Rosenstock J, Denham DS, Prabhakar P, Kjems L, Baron MA. Clinical impact of ITCA 650, a novel drug-device GLP-1 receptor agonist, in uncontrolled type 2 diabetes and very high baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study. Diab Care. 2018;41(3):613\u20139.","journal-title":"Diab Care"},{"issue":"8","key":"698_CR38","first-page":"S146","volume":"24","author":"ET Wittbrodt","year":"2018","unstructured":"Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018;24(8):S146\u201355.","journal-title":"Am J Manag Care"},{"issue":"4","key":"698_CR39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/dom.12596","volume":"18","author":"S Madsbad","year":"2016","unstructured":"Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317\u201332.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"698_CR40","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Htike","year":"2017","unstructured":"Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obes Metab. 2017;19(4):524\u201336.","journal-title":"Diabetes, Obes Metab"},{"issue":"1","key":"698_CR41","doi-asserted-by":"publisher","first-page":"e3070","DOI":"10.1002\/dmrr.3070","volume":"35","author":"R Gentilella","year":"2019","unstructured":"Gentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Diabetes Metab Res Rev. 2019;35(1):e3070.","journal-title":"Diabetes Metab Res Rev."},{"issue":"2","key":"698_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2337\/diacare.29.02.06.dc05-1904","volume":"29","author":"SM Grundy","year":"2006","unstructured":"Grundy SM. Diabetes and coronary risk equivalency: what does it mean? Diab Care. 2006;29(2):457\u201360.","journal-title":"Diab Care"},{"issue":"1","key":"698_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-019-0871-8","volume":"18","author":"LA Leiter","year":"2019","unstructured":"Leiter LA, Bain SC, Hramiak I, J\u00f3dar E, Madsbad S, Gondolf T, et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18(1):73.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"698_CR44","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/dom.13698","volume":"21","author":"S Verma","year":"2019","unstructured":"Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE, et al. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes, Obes Metab. 2019;21(7):1745\u201351.","journal-title":"Diabetes, Obes Metab"},{"issue":"10","key":"698_CR45","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diab Endocrinol. 2019;7(10):776\u201385.","journal-title":"Lancet Diab Endocrinol"},{"issue":"8","key":"698_CR46","first-page":"S146","volume":"24","author":"ET Wittbrodt","year":"2018","unstructured":"Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018;24(8):S146\u201355.","journal-title":"Am J Manag Care"},{"issue":"6","key":"698_CR47","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/dom.13649","volume":"21","author":"KS Boye","year":"2019","unstructured":"Boye KS, Riddle MC, Gerstein HC, Mody R, Garcia-Perez LE, Karanikas CA, et al. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. Diabetes Obes Metab. 2019;21(6):1299\u2013304.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"698_CR48","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/dom.13962","volume":"22","author":"V Sciannameo","year":"2020","unstructured":"Sciannameo V, Berchialla P, Orsi E, Lamacchia O, Morano S, Querci F, et al. Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2020;22(5):817\u201327.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"698_CR49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12933-021-01300-y","volume":"20","author":"V Sciannameo","year":"2021","unstructured":"Sciannameo V, Berchialla P, Avogaro A, Fadini GP. Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):103.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-021-00698-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-021-00698-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-021-00698-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T13:03:09Z","timestamp":1627390989000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-021-00698-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1186\/s13098-021-00698-5","relation":{},"ISSN":["1758-5996"],"issn-type":[{"type":"electronic","value":"1758-5996"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MM participated in advisory board meetings and received speaker\u2019s fees from the following companies: AstraZeneca, Bial, Boeringher-Ingelheim, Lilly, NovoNordisk and Sanofi. CG reports consulting and speaking fees from Astrazeneca, Novo Nordisk, Lilly, Boheringer Ingelheim, MSD and Bayer. JSN reports receiving research funding from AstraZeneca, and Merck sa; and consulting\/speaker\u2019s fees from Abbott, AstraZeneca, Bial, Boehringer Ingelheim, Janssen, Lilly, Medinfar, Merck sa, Merck Sharp & Dohme, Mundipharma, Novartis, Novo Nordisk, Roche, Sanofi, Servier, Tecnimede. LA reports membership of advisory board, consultancy\/ speaker's fees from: Astra-Zeneca, Lilly, Bhoeringer, NovoNordisk and Bial.DC is member of Advisory Boards of Novo-Nordisk, Astra-Zeneca, Eli Lilly, Sanofi-Aventis and is speaker for Novo-Nordisk, Astra-Zeneca, Eli Lilly.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}